antiIL17A

Anti-IL-17A refers to a class of biologic therapies that neutralize interleukin-17A (IL-17A), a proinflammatory cytokine involved in the pathogenesis of several autoimmune conditions. By binding IL-17A, these agents prevent its interaction with IL-17 receptors on various cell types, reducing downstream signaling and the production of inflammatory mediators such as TNF, IL-6, and chemokines. The result is decreased recruitment of neutrophils and dampened inflammatory responses in affected tissues.

Representative agents include secukinumab and ixekizumab, both monoclonal antibodies administered by subcutaneous injection. They have been approved for plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis, with additional approvals for other inflammatory diseases in some regions. Dosing typically involves initial loading or higher-frequency injections followed by maintenance injections every two to four weeks, depending on the product and condition.

Safety and adverse effects: Anti-IL-17A therapies are generally well tolerated but can increase the risk of mucocutaneous candidiasis due to suppression of IL-17A–mediated antifungal defense. Other common adverse events include injection-site reactions and nasopharyngitis. There is a potential risk of serious infections; guidelines typically require screening for latent tuberculosis and other infections before initiation. Use in pregnancy and lactation requires careful consideration, and vaccination status should be reviewed prior to starting therapy.

Developmental status: Ongoing research investigates expanding indications, long-term safety, and head-to-head comparisons with other biologics. Some IL-17 pathway inhibitors target multiple IL-17 family members, broadening or refining the effects beyond IL-17A inhibition.